Skip to main content
AARD
NASDAQ Life Sciences

Aardvark Q3 Loss Widens to $19.2M; Cash Down to $60.3M With Runway Into 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.51
Mkt Cap
$33.265M
52W Low
$0.93
52W High
$16.6
52W Position info
62% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AARD sits 62% above its 52-week low of $0.93 on light trading volume (0.4× avg).

Summary

Aardvark posted a $19.2M Q3 loss and finished September with $60.3M in cash and investments, enough to fund operations through 2027 — but only if it does not restart a Phase 3 ARD-101 program, which will require new financing.


Key Events · Earnings and Guidance · AARD

  • Q3 Loss Widens to $19.2M

    Net loss was $19.2M for the three months ended September 30, 2026 versus $16.3M a year earlier; nine-month loss reached $55.2M versus $40.0M.

  • Cash Falls to $60.3M

    Cash, cash equivalents and short-term investments totaled $60.3M at September 30, 2026, down from $110.0M at December 31, 2025, after $50.0M of operating cash burn in the first nine months.

  • Runway Guided Through 2027

    Management states existing cash funds projected operations through 2027, but says substantial additional capital is needed to complete any new Phase 3 ARD-101 trial; the $150.0M ATM had no shares sold as of September 30, 2026.

  • Options Repriced to $1.26

    On November 6, 2026, 2,445,497 options had exercise prices cut to $1.26, contingent on continued service through November 6, 2027 or a change in control.


Analysis · AARD · Life Sciences

Cash burn is the story here: $50.0M used in operations over nine months left $60.3M of cash and investments at September 30, and management guides to funding through 2027. That runway assumes no new Phase 3 spend, and the company says it will need substantial additional capital to run any new ARD-101 trial. With a $150.0M ATM sitting unused and the stock at $1.51, any raise would be heavily dilutive. The November 6 repricing of 2,445,497 options down to $1.26 is a retention move that also lowers the cash employees would pay on exercise. On top of the clinical reset, the securities class action filed August 14, 2026 adds defense costs and headline risk.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AARD was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.93 to $16.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AARD - Latest Insights

AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.51 info
Change: -$1.58 (-51%) info
Market Cap: $33.265M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $1.51 info
Change: -$2.44 (-62%) info
Market Cap: $33.265M info
AARD
Aug 11, 2026, 5:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $1.51 info
Change: -$5.82 (-79%) info
Market Cap: $33.265M info
AARD
Aug 11, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $1.51 info
Change: -$5.82 (-79%) info
Market Cap: $33.265M info
AARD
Jun 29, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $5.18
Real-time Price: $1.51 info
Change: -$3.67 (-71%) info
Market Cap: $33.265M info